Prevalence, outcome and risk factor associated with vancomycin-resistant Enterococcus faecalis and Enterococcus faecium at a Tertiary Care Hospital in Northern India

Indian Journal of Medical Microbiology
A TripathiK N Prasad

Abstract

To determine the prevalence, genotype, risk factors and mortality in patients having vancomycin-resistant Enterococcus faecalis (VR E. faecalis) and Enterococcus faecium (VR E. faecium) infection or colonisation. A total of 1488 clinical isolates of E. faecalis and E. faecium were tested for vancomycin resistance by phenotypic (disk diffusion, E-test and broth micro-dilution test) and genotypic polymerase chain reaction methods. Records of all 1488 patients who had E. faecalis or E. faecium infection or colonisation were reviewed for the identification of host, hospital and medication related risk factors associated with VR E. faecalis and VR E. faecium. Of 1488 isolates, 118 (7.9%) were vancomycin-resistant and their distributions were as follows: E. faecalis=72 (61%) and E. faecium=46 (39%). All 118 vancomycin-resistant isolates were vanA genotype (minimum inhibitory concentration [MIC] to vancomycin ≥64 μg/ml and MIC to teicoplanin≥32 μg/ml) and none of the isolates was vanB genotype. Multivariate logistic regression analysis identified ventilator support and hospital stay for ≥48 h as independent risk factors associated with VR E. faecalis and VR E. faecium infection or colonisation. Hospital stay≥48 h was the only independ...Continue Reading

References

Mar 15, 1990·The New England Journal of Medicine·P RuizA D Schreiber
Apr 1, 1989·Journal of Clinical Microbiology·R R Facklam, M D Collins
Jun 1, 1988·American Journal of Infection Control·J S GarnerJ M Hughes
Jun 1, 1993·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S HandwergerB Walters
Dec 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M B EdmondR P Wenzel
Jun 1, 1997·Infectious Disease Clinics of North America·J M Boyce
Nov 21, 2001·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M ScagnelliR Fontana
Jul 27, 2002·Emerging Infectious Diseases·Yehuda CarmeliMatthew H Samore
Oct 27, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·UNKNOWN European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee
Jun 12, 2013·PLoS Genetics·Renata C MatosPascale Serror

❮ Previous
Next ❯

Citations

Aug 18, 2016·Journal of Global Antimicrobial Resistance·Nadjette BourafaJean-Marc Rolain
Sep 21, 2016·The Journal of Hospital Infection·N Monteserin, E Larson
Apr 11, 2015·Medical Journal, Armed Forces India·Puneet BhattMayuri Kulkarni
Feb 28, 2019·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Roberto VivasSona Jain
Sep 6, 2019·Antimicrobial Resistance and Infection Control·Robby MarkwartAnnicka Reuss
Sep 5, 2020·Indian Journal of Medical Microbiology·Ayan Kumar DasPreet Simran Kaur
Feb 17, 2021·Indian Journal of Medical Microbiology·Ayan Kumar DasPreet Simran Kaur

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.